How to invest in biotechnology: the healthcare sector’s high-growth area
How to invest in biotechnology: the healthcare sector’s high-growth area
Dr Mike Tubbs provides an overview of this thriving industry, whose latest triumphs include the Covid-19 vaccines. He examines the best investment str…
14 May 2021
Vaccine patents: a bitter pill for drug companies
Vaccine patents: a bitter pill for drug companies
The US has suggested waiving drug companies’ vaccine patents to hasten the defeat of Covid-19, sending their share prices down.
14 May 2021
AstraZeneca’s shareholders rebel over pay
AstraZeneca’s shareholders rebel over pay
Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
14 May 2021
Merck: the good value biotech stock that has cornered the cancer market
Merck: the good value biotech stock that has cornered the cancer market
Merck, the biopharma giant, dominates the biggest disease sector and looks reasonably valued, says Dr Mike Tubbs.
27 Apr 2021
Activist investor Elliott takes takes a stake in Glaxo
Activist investor Elliott takes takes a stake in Glaxo
Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.
22 Apr 2021
Moderna’s Stéphane Bancel: the maths nerd who struck vaccine gold
Moderna’s Stéphane Bancel: the maths nerd who struck vaccine gold
A decade ago, Stéphane Bancel took a gamble and joined a fledgling start-up working on an unproven new technology. The gamble paid off with the rise o…
17 Apr 2021
How the vaccine wars will harm us all
How the vaccine wars will harm us all
Grabbing and hoarding vaccine supplies, or even manufacturing one’s own, might seem to make sense for a state in an emergency. But the damage done to …
27 Mar 2021
Subscribe to MoneyWeek and get your first six issues FREE
Subscribe to MoneyWeek now and get your first six magazine issues absolutely FREE
AstraZeneca’s Pascal Soriot: in the crossfire of the vaccine wars
AstraZeneca’s Pascal Soriot: in the crossfire of the vaccine wars
AstraZeneca’s boss Pascal Soriot was winning plaudits for his stewardship when the Covid-19 pandemic struck. Since then, he’s been having a hard time …
27 Mar 2021
Scientific-instrument companies are a global success – here's how to play them
Scientific-instrument companies are a global success – here's how to play them
Companies delivering scientific instruments – products to measure and analyse our world – are crucial to sectors ranging from telecommunications to ph…
26 Mar 2021
Three winners of the long-term biotech boom
Three winners of the long-term biotech boom
Professional investor Marek Poszepcynski of the International Biotechnology Trust picks three biotech stocks with good pipelines, strong management te…
22 Mar 2021
The unscientific criticism of AstraZeneca could do lasting damage
The unscientific criticism of AstraZeneca could do lasting damage
Several European countries have suspended their use of AstraZeneca's Covid vaccine – for no good scientific reason. Matthew Partridge reports.
18 Mar 2021
Johnson & Johnson vaccine approval is another shot in the arm for the world
Johnson & Johnson vaccine approval is another shot in the arm for the world
Johnson & Johnson’s vaccine has been approved in the US, a sign that the world is making solid progress against Covid-19. Matthew Partridge reports
4 Mar 2021
How to invest in the latest developments in hearing technology
How to invest in the latest developments in hearing technology
Traditionally dismissed as a relative backwater, this branch of medicine is about to move into the limelight thanks to ageing populations and major br…
19 Feb 2021
Vanquishing the virus: the race to make vaccines for Covid-19
Vanquishing the virus: the race to make vaccines for Covid-19
The extraordinarily rapid development of effective treatments against the coronavirus is a triumph of biotechnology, says Dr Mike Tubbs. He reviews th…
12 Feb 2021
Vexing vaccine delays hit drug firms
Vexing vaccine delays hit drug firms
AstraZeneca and Pfizer are being attacked by the EU over what it claims are delays in delivering the Covid vaccine.
28 Jan 2021
AstraZeneca turns the tables as it acquires US pharmaceutical firm Alexion
AstraZeneca turns the tables as it acquires US pharmaceutical firm Alexion
AstraZeneca, the British pharma giant, was almost swallowed up by Pfizer a few years ago. Now it has struck a megadeal of its own. Matthew Partridge r…
17 Dec 2020
The lessons of “Operation Warp Speed” – the race to produce a vaccine
The lessons of “Operation Warp Speed” – the race to produce a vaccine
Governments and companies can learn from the extraordinary global effort to create a vaccine to defeat Covid-19, says Matthew Lynn.
13 Dec 2020
The MoneyWeek Podcast: Barry Norris on why he's shorting vaccine-makers
The MoneyWeek Podcast: Barry Norris on why he's shorting vaccine-makers
The news of Covid vaccines has delighted many. But not Argonaut Capital's Barry Norris. He tells Merryn why vaccines aren't the panacea people think t…
3 Dec 2020
Big Pharma deserves its reward for coming up with Covid-19 vaccines
Big Pharma deserves its reward for coming up with Covid-19 vaccines
Calls to restrain drug companies' profits from making Covid-19 vaccines are misplaced and would do more harm than good, says Matthew Lynn
29 Nov 2020
More good news as AstraZeneca finds a third Covid vaccine
More good news as AstraZeneca finds a third Covid vaccine
Another week, another Covid-19 vaccine. This one from AstraZeneca and Oxford University is homegrown and ready to roll out fast. Matthew Partridge rep…
26 Nov 2020
Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine
Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine
Ugur Sahin and Özlem Türeci are an unassuming Turkish-German couple who had already made their fortune as biotech entrepreneurs when a strange new vi…
21 Nov 2020
Moderna’s “stunning” second vaccine
Moderna’s “stunning” second vaccine
America’s Moderna has come up with a vaccine even more promising than last week’s offering from Pfizer and BioNTech. Matthew Partridge reports
19 Nov 2020